Fig. 2

a Primary treatment failure* among Latin American patients randomized to early combination versus initial monotherapy. CI confidence interval, HR hazard ratio, LatAm Latin America. *Primary treatment failure is defined as HbA1c ≥ 7.0% at two consecutive scheduled visits, starting from 13 weeks after randomization. The time to initial treatment failure is the time from randomization to the second consecutive scheduled visits with HbA1c ≥ 7.0%. Patients who discontinued the study for any reason during period 1 were censored at the date of discontinuation. Patients with HbA1c < 7.0% (or whose measurement ≥ 7.0% was not confirmed at next scheduled visit) were censored at the date of last study visit. The Kaplan–Meier estimates were performed for patients who had received at least one randomized medication and one post-randomization efficacy parameter assessed. b Primary treatment failure* among all patients from VERIFY randomized to early combination versus initial monotherapy. CI, confidence interval; HR, hazard ratio. *Primary treatment failure is defined as HbA1c ≥ 7.0% at two consecutive scheduled visits, starting from 13 weeks after randomization. The time to initial treatment failure is the time from randomization to the second consecutive scheduled visits with HbA1c ≥ 7.0%. Patients who discontinued the study for any reason during period 1 were censored at the date of discontinuation. Patients with HbA1c < 7.0% (or whose measurement ≥ 7.0% was not confirmed at next scheduled visit) were censored at the date of last study visit. The Kaplan–Meier estimates were performed for patients who had received at least one randomized medication and one post-randomization efficacy parameter assessed